Drug Profile
Research programme: insulin based therapeutics - Albireo Pharma
Alternative Names: BIOD-104; BIOD-620; BIOD-Glucose-responsive Basal; BIOD-Smart Basal; Glucose-sensing basal insulin; Injectable smart basal insulin; VialogLatest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator Biodel
- Developer Albireo Pharma
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 02 Mar 2023 Albireo Pharma has been acquired by Ipsen
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (SC, Injection)
- 18 Nov 2014 Biodel has patent protection for its ultra-rapid-acting insulin formulations in Europe